Argireline (Acetyl Hexapeptide-8)
Overview
Argireline is Acetyl Hexapeptide-8, a synthetic neuromodulatory peptide (Ac-EEMQRR-NH₂) modelled on the N-terminal end of SNAP-25, a protein in the machinery that releases neurotransmitters. In topical research it is studied as a way to reduce the micro-contractions behind dynamic expression lines — a mechanism often described as a topically-applied research alternative to injectable approaches. Its ends are capped (N-acetyl, C-amide) so it resists the enzymes that would otherwise trim a short peptide.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 616204-22-9 |
| INCI name | Acetyl Hexapeptide-8 (formerly Acetyl Hexapeptide-3) |
| Amino-acid sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂ |
| One-letter code | Ac-EEMQRR-NH₂ |
| Molecular formula | C₃₄H₆₀N₁₄O₁₂S |
| Molecular weight | 888.47 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Neuromodulatory peptide (SNARE inhibitor)
- Origin
- Modelled on the SNAP-25 N-terminus
- Research status
- Extensive clinical research
- Typical route
- Topical
- Reference trade name
- Argireline™ (Lipotec)
- Key feature
- Studied for topical reduction of muscle micro-contraction
Mechanism of Action
Nerve endings release acetylcholine by fusing vesicles to the cell membrane, and that fusion depends on the SNARE complex assembling correctly. Argireline is studied as a fragment that resembles part of SNAP-25, one of the SNARE proteins, and is investigated for competing with it during assembly. The result explored in models is a softer signal for muscle contraction — the peptide is described as acting downstream of calcium entry rather than blocking calcium itself.
| Component | Research description |
|---|---|
| Primary target | The SNARE assembly (SNAP-25 / syntaxin / VAMP interaction). |
| Inhibition mode | Studied as competitive interference at the SNAP-25 N-terminal region. |
| Neurotransmitter | Associated with reduced acetylcholine release at the neuromuscular junction. |
| Downstream effect | Explored as decreased muscle-contraction amplitude in models. |
| Calcium dependence | Reported to act after Ca²⁺ influx, not on the calcium signal itself. |
Areas where the topical effect is typically studied: expression lines generally, the periorbital area (crow’s-feet region), and forehead lines.
Pharmacology
| Parameter | Value |
|---|---|
| logP | −1.7 (hydrophilic) |
| pKa | ≈ 12.5 (arginine guanidinium), 4.0 (glutamic acid) |
| Topical bioavailability | ~2–5% (usually needs penetration enhancers or liposomes) |
| Stability | High — capped N-acetyl and C-amide ends resist exopeptidases |
| Protein binding | Low to moderate |
| Metabolism | Proteolytic breakdown in the epidermis |
| Route of administration | Topical |
Research Evidence
Argireline is the most-studied topical neuromodulatory peptide and is the usual comparator for newer analogues such as SNAP-8, with both mechanistic (preclinical) and human (clinical) studies.
Expression-line research
Central to topical research on dynamic expression lines and periorbital/forehead areas.
SNARE biology
A model tool for studying peptide interference with vesicle-fusion machinery.
Formulation studies
Investigated for delivery, since a hydrophilic peptide needs help crossing the stratum corneum.
Combination research
Frequently paired with matrikines (e.g. Matrixyl) in multi-mechanism formulation studies.
Preclinical research — representative models and what they investigate:
| Model | Research focus | Reference |
|---|---|---|
| SNAP-25 competitive binding assay | Interference with SNARE assembly | Blanes-Mira C, et al. (2002) |
| Neuronal cell model (PC12) | Stimulated neurotransmitter release | Schagen SK (2017, review) |
| Nerve–muscle preparation | Muscle-contraction amplitude | Blanes-Mira C, et al. (2002) |
| Human skin (ex vivo) | Peptide penetration | Gorouhi F, Maibach HI (2009) |
Clinical research — the types of human study in which the ingredient is examined:
| Study type | Endpoints studied | Reference |
|---|---|---|
| Topical solution / cream | Expression-line and crow’s-feet appearance | Blanes-Mira C, et al. (2002) |
| Anti-aging formulations | Wrinkle roughness and depth | Lupo MP, Cole AL (2007) |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Interferes with SNARE assembly, reducing neurotransmitter release | SNAP-25 / neuronal models | Blanes-Mira C et al., 2002 |
| Reduced appearance of expression lines | topical human study | Blanes-Mira C et al., 2002 |
For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.
Formulation & Dosing Reference
| Parameter | Value |
|---|---|
| Typical topical concentration | 1–10% (w/w) |
| Common working range | 5–10% |
| Solubility in water | ≥ 50 mg/mL |
| Solubility in ethanol | Moderate (≈ 10 mg/mL) |
| Solubility in DMSO | ≥ 50 mg/mL |
| Recommended formulation pH | 5.0–7.0 |
| Storage (powder) | 2–8°C, sealed, dry, protected from light |
- The EU cosmetic-ingredient database lists a maximum use level of 10% for this ingredient.
- The single methionine residue can oxidise in solution; antioxidants (e.g. BHT, tocopherol) are commonly added to formulations.
Safety Profile
| Assessment | Reported result |
|---|---|
| Acute oral toxicity (rat) | LD50 > 2000 mg/kg |
| Dermal irritation (rabbit) | Non-irritant at 10% |
| Ocular irritation (rabbit) | Non-irritant |
| Skin sensitization (GPMT) | Non-sensitizing |
| Mutagenicity (Ames) | Negative |
| Maximum use level (EU CosIng) | 10% |
| INCI status | Approved cosmetic ingredient (Acetyl Hexapeptide-8) |
Physicochemical Properties
| Property | Value |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility in water | ≥ 50 mg/mL |
| Solubility in DMSO | ≥ 50 mg/mL |
| Melting point | > 200°C (decomposition) |
| pH (1% aqueous) | 5.0–6.0 |
| Isoelectric point (pI) | ≈ 10.8 |
| Net charge at pH 7 | ≈ +2 |
| Light sensitivity | Low |
Synthesis & Manufacturing
Argireline is built by solid-phase peptide synthesis on an amide resin so the finished peptide carries a C-terminal amide, then acetylated at the N-terminus. The two arginines in a row and the oxidation-prone methionine make coupling and cleavage the parts that need the most care.
| Step | Detail |
|---|---|
| Strategy | Solid-phase peptide synthesis, Fmoc/tBu chemistry |
| Resin | Rink amide MBHA resin (C-terminal amide) |
| Coupling | HATU / HBTU with DIPEA |
| Side-chain protection | Glu(OtBu), Gln(Trt), Arg(Pbf); Met unprotected |
| N-terminal acetylation | Acetic anhydride / DIPEA after final Fmoc removal |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5), with scavengers |
| Purification | Preparative RP-HPLC (C18, TFA/ACN gradient) |
- The consecutive Arg-Arg often needs extended or double coupling because of steric hindrance.
- Methionine can oxidise during cleavage; scavengers such as TIPS or thioanisole limit sulfoxide formation.
- Complete N-acetylation is checked as a characteristic +42 Da mass shift and the loss of the free N-terminal amine peak.
Analytical Methods
| Method | Purpose | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| ESI-MS (positive mode) | Identity / mass | m/z consistent with the acetylated hexapeptide amide |
| Amino-acid analysis | Composition | Glu₂ : Met : Gln : Arg₂ |
| LC-MS/MS | End-group confirmation | N-acetylation and C-amidation confirmed |
| RP-HPLC | Methionine sulfoxide | Oxidised species kept low |
| Ion chromatography | Residual TFA | Kept low |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: 5–30% B over ~20 min · Flow rate: 1.0 mL/min
- Detection: UV 214 nm
Stability Data
The capped ends make Argireline stable as a powder and in finished products; the main thing to manage is oxidation of the single methionine residue in solution.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized powder, 2–8°C, dark | ≥ 24 months | No significant degradation |
| Lyophilized powder, 25°C, dark | ≥ 12 months | Minimal; low Met oxidation |
| Aqueous solution, pH 5.5, 4°C, dark | ≈ 14 days | Minor degradation |
| Aqueous solution, pH 5.5, 25°C | ≈ 7 days | Minor degradation |
| Formulated serum / cream, 25°C | 12+ months | Peptide largely retained |
| Light exposure (ICH Q1B) | Standard | Light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable |
- Both the acetylated N-terminus and amidated C-terminus resist exopeptidase cleavage, giving good stability.
- The single methionine can oxidise to methionine sulfoxide in warm solution; antioxidants (BHT, tocopherol) are commonly added.
- Optimal stability is pH 5.0–7.0; avoid strong oxidising agents in formulation.
Selected References
Representative peer-reviewed literature on Acetyl Hexapeptide-8 (Argireline). Listed for research reference.
- Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. International Journal of Cosmetic Science, 2002.
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
- Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.
- Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS; end-group modifications verified
- Research samples through to bulk, with worldwide delivery
- Custom sequences and packaging on request
Need Argireline — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
